Market Scenario:
Global Cell Viability Assays market is expected to grow significantly over the forecast period. It is estimated that the global cell Viability Assays market is expected to register a CAGR ~ 9.2% during the forecast period of 2018–2023.
Cell-based assays are techniques used for the screening collections of compounds to find out if the test molecules have any effect on cell proliferation or show direct cytotoxic effects that eventually lead to cell death. The measurement of cell viability plays a significant role in all forms of cell culture. The main application of cell viability is to determine whether the cells are alive. For instance, in cancer research, cell viability assays are used to confirm the killing of tumor cells and to verify the survival of normal cells.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6391
The increasing prevalence of various chronic diseases such as cancer, rising availability of funds for cell-based research, and increasing demands for cell-based assays in research are likely to drive the growth in this market. According to the National Cancer Institute, an estimated 1,685,210 new cases of cancer were diagnosed in the US in 2016. Additionally, the rising focus on the development of cell-based therapeutics is also expected to contribute to the growth of the market. On the other hand, the high cost of instruments may hinder the growth of the market during the forecast period.
Key Players
- Thermo Fisher Scientific
- Merck KGaA
- Bio-Rad Laboratories
- G E Healthcare
- Danaher Corporation
- Becton, Dickinson and Company
- Promega Corporation
- Biotium
- Abcam plc
- Creative Bioarray
- Biotek Instruments
- PerkinElmer
Segmentation
The market has been segmented into products, cell type, applications, and end-user.
The market, on the basis of products, has been segmented into consumables and instruments.
The consumables segment has been further divided into reagents, assay kits, and microplates. The Assay kits segment has been further segmented into tetrazolium reduction assay kits, resazurin cell Viability Assays kits, calcein-Am cell Viability Assays kits and other assay kits. Furthermore, tetrazolium assay kits have been classified into MIT assay kits and other tetrazolium assay kits.
The instruments have been segmented into automated cell counters, flow cytometers, spectrophotometers, and cell imaging & analysis systems.
The market, by applications, has been segmented into stem cell research, clinical & diagnostic applications, drug discovery & development, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & diagnostic laboratories and others.
The market, by cell type, has been segmented into human cells, microbial cells, and animal cells.
The European cell Viability Assays market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The cell Viability Assays market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cell Viability Assays market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market
Geographically, the Americas is anticipated to dominate the global cell Viability Assays market owing to a well-developed healthcare sector, rising prevalence of infectious and chronic diseases and growing healthcare expenditure. According to an article published by the Centers for Medicare and Medicaid Services in August 2018, the US healthcare spending had reached USD 3.3 trillion in 2016. Europe is expected to hold the second largest position in the global cell Viability Assays market. The market growth in this region is attributed to the growing prevalence of chronic diseases and increasing healthcare expenditure. According to a report published by EU observer in September 2014, more than the one-third population of Europe above the age of 15 years in suffering from a chronic disease and 2 in every 3 people reaching the age of retirement have at least 2 chronic diseases.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising number of stem cell, proteomics, and genomics research activities. Also, increased expenditure in the healthcare sector is expected to boost the growth in this market.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Browse Complete 90 Pages Premium Research Report Enabled with 92 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cell-viability-assays-market-6391
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312